WAL0921
Rare Kidney Diseases
Phase 2Active
Key Facts
About Walden Biosciences
Walden Biosciences is a private, preclinical to clinical-stage biotech dedicated to creating direct kidney-targeted therapies for a range of kidney diseases. The company is advancing a pipeline of novel candidates, with its lead asset, WAL0921, progressing toward Phase 2 trials for rare kidney diseases as of late 2025. Operating from the biotech hub of Cambridge, Walden is positioning itself to address significant unmet medical needs in nephrology through a focused therapeutic approach.
View full company profile